Advance Search
SUN Yumei. Effect of valsartan combined with carvedilol intreating chronic cardiac failure and its effect on plasma brain natriuretic peptide expression[J]. Journal of Clinical Medicine in Practice, 2019, 23(8): 72-74. DOI: 10.7619/jcmp.201908020
Citation: SUN Yumei. Effect of valsartan combined with carvedilol intreating chronic cardiac failure and its effect on plasma brain natriuretic peptide expression[J]. Journal of Clinical Medicine in Practice, 2019, 23(8): 72-74. DOI: 10.7619/jcmp.201908020
shu

Effect of valsartan combined with carvedilol intreating chronic cardiac failure and its effect on plasma brain natriuretic peptide expression

  • Department of Cardiovascular Medicine, Changqing Oilfield Staff Hospital, Xi′an, Shaanxi, 710201

More Information
  • Received Date: January 12, 2019
  • Accepted Date: February 15, 2019
  • Available Online: December 03, 2020
  • Published Date: April 27, 2019
    Graphical Abstract
    • Abstract
  •   Objective  To analyze the effect of valsartan combined with carvedilol intreating chronic heart failure (CHF) and its effect on the expression level of plasma brain natriuretic peptide(BNP).
      Methods  Seventy-nine CHF patients admitted to our hospital were divided into control group (n=39) and observation group (n=40) according to the random number table method. The control group was treated with valsartan, while the observation group was treated with valsartan combined with carvedilol. The levels of cardiac function and BNP expression were compared between the two groups.
      Results  The improvement of cardiac function in the observation group was better, and the BNP expression was lower after treatment than that in the control group(P < 0.05). During the treatment, there was no liver or kidney abnormality between the two groups, and there was no significant difference in the incidence of adverse reactions (P>0.05).
      Conclusion  Valsartan combined with carvedilol in the treatment of chronic heart failure has an ideal therapeutic effect, which can reduce the level of plasma brain natriuretic peptide expression.
    • FullText(HTML)
    • References (18)
  • [1]
    董洪玲, 王中鲁, 张亮, 等. 慢性心力衰竭的治疗进展[J]. 中国循证心血管医学杂志, 2017, 9(2): 246-248. doi: 10.3969/j.issn.1674-4055.2017.02.36
    [2]
    倪晶宇, 李澜, 李敏, 等. 慢性心力衰竭与能量代谢重构关系的研究进展[J]. 中国临床药理学杂志, 2017, 33(5): 474-477. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201705025.htm
    [3]
    邱伯雍, 王永霞. 慢性心力衰竭流行病学及防治研究进展[J]. 中华实用诊断与治疗杂志, 2017, 31(6): 619-621. https://www.cnki.com.cn/Article/CJFDTOTAL-HNZD201706034.htm
    [4]
    田桂芳, 杨秀玲, 戴妍妍, 等. 心力衰竭超声指数及N末端脑钠肽前体对慢性心力衰竭患者心功能的评估价值[J]. 中国循证心血管医学杂志, 2017, 9(4): 464-466. doi: 10.3969/j.issn.1674-4055.2017.04.22
    [5]
    喻盛杰, 陈威. 慢性心力衰竭患者血清CA125及BNP水平与心功能的相关性[J]. 山东医药, 2017, 57(33): 49-50. doi: 10.3969/j.issn.1002-266X.2017.33.016
    [6]
    中华医学会心血管病学分会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2): 3-10. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS201605007.htm
    [7]
    才让卓玛, 陈秀英, 连心龙, 等. 原发性高血压合并慢性心力衰竭患者心脏结构改变及危险因素分析[J]. 疑难病杂志, 2017, 16(9): 865-868. doi: 10.3969/j.issn.1671-6450.2017.09.001
    [8]
    林传钦, 翟秀丽, 邓托. 120例慢性心力衰竭患者再入院的危险因素分析[J]. 实用预防医学, 2018, 25(4): 483-485. doi: 10.3969/j.issn.1006-3110.2018.04.027
    [9]
    黄樱硕, 王倩倩, 黄蔚, 等. 老年慢性射血分数保留心力衰竭的危险因素分析及其与脑啡肽酶的相关性研究[J]. 中华老年多器官疾病杂志, 2017, 16(11): 807-811. doi: 10.11915/j.issn.1671-5403.2017.11.188
    [10]
    王霞, 郭俊林, 黄小鲁, 等. 重度慢性心力衰竭患者近期预后影响因素的回顾性分析[J]. 实用预防医学, 2017, 24(5): 552-554. doi: 10.3969/j.issn.1006-3110.2017.05.011
    [11]
    曹小彤, 徐翠荣, 王静静. 慢性心力衰竭患者生活质量影响因素的病例对照研究[J]. 护理学报, 2017, 24(23): 5-8. https://www.cnki.com.cn/Article/CJFDTOTAL-NFHL201723003.htm
    [12]
    张钿, 金钊, 白晓军. 缬沙坦对慢性心力衰竭患者心功能、心室重构及基质金属蛋白酶的影响[J]. 中国心血管病研究, 2017, 15(8): 744-747. doi: 10.3969/j.issn.1672-5301.2017.08.019
    [13]
    陈聪, 张凌宇, 杨永聪, 等. 缬沙坦联合胺碘酮对慢性心力衰竭合并室性期前收缩患者Tp-e间期及室性期前收缩指数的影响[J]. 心脑血管病防治, 2017, 17(1): 39-41. https://www.cnki.com.cn/Article/CJFDTOTAL-XXFZ201701014.htm
    [14]
    叶慧玲, 聂劼, 肖利利, 等. 缬沙坦治疗高血压伴心力衰竭的疗效及其对血清hs-CRP水平的影响[J]. 海南医学, 2017, 28(20): 3279-3281. doi: 10.3969/j.issn.1003-6350.2017.20.004
    [15]
    梁芳洁, 许嘉鸿. 倍他洛克、卡维地洛和慢性心力衰竭患者临床转归的相关性分析[J]. 中国实验诊断学, 2017, 21(9): 1513-1515. doi: 10.3969/j.issn.1007-4287.2017.09.009
    [16]
    曹新营, 王志军, 杨文琦, 等. 卡维地洛对CHF病人细胞免疫功能及临床疗效的影响[J]. 中西医结合心脑血管病杂志, 2017, 15(16): 2010-2012. doi: 10.3969/j.issn.1672-1349.2017.16.017
    [17]
    冯卫涛, 李薇, 栾荣华. 卡维地洛联合缬沙坦治疗慢性心力衰竭的临床效果[J]. 心血管康复医学杂志, 2017, 26(3): 310-313. doi: 10.3969/j.issn.1008-0074.2017.03.022
    [18]
    谷晨星, 黄党生, 孙红岩. 重组人脑利钠肽对慢性心力衰竭患者血浆sRAGE、NF-κB及心功能的影响[J]. 中国医药导报, 2017, 14(5): 63-66. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201705017.htm
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (402) PDF downloads (8) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return